Form D · Biotechnology
Ovala, Inc.
Pittsburgh, PA · CIK 0001936997
Offering snapshot reported Mar 31, 2026 · SEC filing
- Reported sold
- $3.26M Offering amount: $13M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 16, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 31, 2026 | Initial | $3,257,155 | No comparison | 8 | SEC filing |
| Jul 7, 2022 | Initial | $3,863,173 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-578611
Amounts include conversion of outstanding convertible securities.
Source: Form D, filed Mar 31, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen Bollinger | Director, Executive |
| Brad Petersen | Director |
| Christopher Petersen | Director |
| Richard Petersen | Director |
| Jeffrey Quillen | Director |
| John Sipple | Executive |
| Michael Tovian | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2366 Golden Mile Highway Box 505
Pittsburgh, PA, 15239
Pittsburgh, PA, 15239